Drug Profile

CTX 203

Alternative Names: CTX-203

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Character Biosciences
Class Eye disorder therapies
Mechanism of Action ATP binding cassette transporter 1 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Age-related macular degeneration

Most Recent Events

07 Feb 2025 CTX 203 is available for licensing as of 07 Feb 2025. https://www.characterbio.com/
07 Feb 2025 Preclinical trials in Age-related macular degeneration in USA (unspecified route), before February 2025 (Character Biosciences pipeline, February 2025)
07 Feb 2025 Character Biosciences plans clinical trial in Age-related macular degeneration in 2025 (Character Biosciences pipeline, February 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com